Skeletal muscle sodium channelopathies.
OBJECTIVE
This is an update on skeletal muscle sodium channelopathies since knowledge in the field have dramatically increased in the past years.


RESULTS
The relationship between two phenotypes and SCN4A has been confirmed with additional cases that remain extremely rare: severe neonatal episodic laryngospasm mimicking encephalopathy, which should be actively searched for since patients respond well to sodium channel blockers; congenital myasthenic syndromes, which have the particularity to be the first recessive Nav1.4 channelopathy. Deep DNA sequencing suggests the contribution of other ion channels in the clinical expressivity of sodium channelopathies, which may be one of the factors modulating the latter. The increased knowledge of channel molecular structure, the quantity of sodium channel blockers, and the availability of preclinical models would permit a most personalized choice of medication for patients suffering from these debilitating neuromuscular diseases.


CONCLUSIONS
Advances in the understanding of the molecular structure of voltage-gated sodium channels, as well as availability of preclinical models, would lead to improved medical care of patients suffering from skeletal muscle, as well as other sodium channelopathies.
aINSERM U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière - ICM bAP-HP, Hôpital de la Pitié-Salpêtrière, Département des Maladies du Système Nerveux, Paris, France.
Sophie
S
Nicole
Bertrand
B
Fontaine
D053447:Channelopathies / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D006801:Humans; D018482:Muscle, Skeletal / Q000503:physiopathology*; D009135:Muscular Diseases / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D061566:Voltage-Gated Sodium Channels / Q000235:genetics*
D061566:Voltage-Gated Sodium Channels